This topic contains a solution. Click here to go to the answer

Author Question: Which statement correctly describes non-celiac gluten sensitivity? a. Rye, barley, and wheat must ... (Read 113 times)

bclement10

  • Hero Member
  • *****
  • Posts: 560
Which statement correctly describes non-celiac gluten sensitivity?
 a. Rye, barley, and wheat must be removed from the diet to relieve the condition.
 b. Gluten consumption elicits the production of antibodies related to gluten intolerance.
  c. Adverse reactions are similar to those of celiac disease when gluten is consumed.
  d. Symptoms include weight gain and joint pain.
 e. Genetic markers are irrelevant because the disease is not hereditary.

Question 2

Ketones can meet some of the nervous system's energy needs.
 
 
  Indicate whether the statement is true or false



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

jharrington11

  • Sr. Member
  • ****
  • Posts: 365
Answer to Question 1

c

Answer to Question 2

T




bclement10

  • Member
  • Posts: 560
Reply 2 on: Aug 20, 2018
:D TYSM


marict

  • Member
  • Posts: 304
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

Essential fatty acids have been shown to be effective against ulcers, asthma, dental cavities, and skin disorders such as acne.

Did you know?

The people with the highest levels of LDL are Mexican American males and non-Hispanic black females.

Did you know?

Cutaneous mucormycosis is a rare fungal infection that has been fatal in at least 29% of cases, and in as many as 83% of cases, depending on the patient's health prior to infection. It has occurred often after natural disasters such as tornados, and early treatment is essential.

Did you know?

As many as 20% of Americans have been infected by the fungus known as Histoplasmosis. While most people are asymptomatic or only have slight symptoms, infection can progress to a rapid and potentially fatal superinfection.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library